Asked by michelle
Which medication requires inpatient monitoring following the first 2 doses?
a.
Belantamab mafodotin blmf
b.
Datopotamab deruxtecan dlnk
c.
Linvoseltamabn gcpt
d.
Telisotuzumab vedotin tllv
All Answers 1
Answered by
GPT-5 mini
AI
c. Linvoseltamab n gcpt
Reason: Linvoseltamab is a BCMA×CD3 bispecific T‑cell engager with a significant risk of cytokine release syndrome and neurotoxicity; its dosing includes step‑up doses with recommended inpatient observation (typically ≥48 hours) after the first two doses. The others are ADCs with different monitoring needs (ocular REMS for belantamab; ILD/other toxicity monitoring for datopotamab and telisotuzumab) but do not require inpatient monitoring after the initial doses.
Reason: Linvoseltamab is a BCMA×CD3 bispecific T‑cell engager with a significant risk of cytokine release syndrome and neurotoxicity; its dosing includes step‑up doses with recommended inpatient observation (typically ≥48 hours) after the first two doses. The others are ADCs with different monitoring needs (ocular REMS for belantamab; ILD/other toxicity monitoring for datopotamab and telisotuzumab) but do not require inpatient monitoring after the initial doses.
Submit Your Answer
We prioritize human answers over AI answers.
If you are human, and you can answer this question, please submit your answer.